RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.37
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$34.13

10 Nov
2026

-0.140

OPEN

$34.30

-0.41%

HIGH

$34.39

1,281,500

LOW

$34.07

TARGET
$40.875 19.8% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . SHG . SLD . SOM . TRJ .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY27
Forecast		 FY28
Forecast
EPS (cps) 188.6 xxx
DPS (cps) 41.2 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 18.0 xxx
Dividend Yield 1.2% xxx
Div Pay Ratio(%) 21.8% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.56%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.03

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 19/08 - (franking ex-div 6.55c)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx154.5
DPS All xxxxxxxxxxxxxxx35.2
Sales/Revenue xxxxxxxxxxxxxxx8,343.1 M
Book Value Per Share xxxxxxxxxxxxxxx659.0
Net Operating Cash Flow xxxxxxxxxxxxxxx2,664.9 M
Net Profit Margin xxxxxxxxxxxxxxx26.94 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx24.16 %
Return on Invested Capital xxxxxxxxxxxxxxx21.80 %
Return on Assets xxxxxxxxxxxxxxx17.69 %
Return on Equity xxxxxxxxxxxxxxx24.16 %
Return on Total Capital xxxxxxxxxxxxxxx26.89 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,918.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx417 M
Long Term Debt xxxxxxxxxxxxxxx775 M
Total Debt xxxxxxxxxxxxxxx1,192 M
Goodwill - Gross xxxxxxxxxxxxxxx4,200 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx2,126 M
Price To Book Value xxxxxxxxxxxxxxx4.38

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx261.5 M
Capex % of Sales xxxxxxxxxxxxxxx3.13 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,316 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx2,189 M
Research & Development xxxxxxxxxxxxxxx558 M
Investments - Total xxxxxxxxxxxxxxx227 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

2

xxxxxxxxx xx xxxxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

02/11/2026

3

Neutral

$38.50

12.80%

Following ResMed's 1Q results, Citi raises its target to $38.50 from $34 and retains a Neutral rating.

Sales forecasts increase by around 1% and earnings estimates by 1%–2%, with further upside possible if double-digit mask growth continues.

The potential return of competitor Philips in the US market remains a risk, the analyst highlights.

*****.

At first glance, Citi expects the first quarter results from ResMed will be well received, as gross margin and costs were better than expected. The outperformance occurred largely outside of the Americas.

Revenue was up 6% and the core gross margin was 62.5%, up 43 basis points year on year. Devices revenue was up 6% and masks and other categories up 10%.

FY27 revenue growth guidance is unchanged as is the EPS range of US$12.00–US$12.25.

Some further questions are expected by the broker around gross margin sequencing throughout the year amid unchanged EPS guidance.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxx xx xxxxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

03/11/2026

2

Overweight

$38.70

13.39%

Jarden maintains an Overweight rating for ResMed with its target price increased to $38.70 from $38.50 following a strong 1Q27 result where non-GAAP NPAT beat consensus expectations by 9%.

Jarden highlights that revenue came in 2% ahead of consensus, while gross margin outperformed by 60 basis points.

The underlying business demonstrated robustness, underpinned by 8% growth in US Sleep Devices, and the analyst expects inflationary pressures to be effectively managed through pricing increases and efficiency measures.

Management reiterated its full-year revenue and EPS guidance despite the strong start to the period.
Access Extra Coverage Research History >

RMD STOCK CHART

FNArena News on RMD

1
Weekly Ratings, Targets, Forecast Changes – 06-11-26

Nov 09 2026 - Weekly Reports
2
FNArena Corporate Results Monitor – 06-11-2026

Nov 06 2026 - Australia
3
Next Week At A Glance – 9-13 Nov 2026

Nov 06 2026 - Weekly Reports
4
In Case You Missed It – BC Extra Upgrades & Downgrades – 06-11-26

Nov 06 2026 - Weekly Reports
5
Rudi’s View: Previews To November Results

Nov 05 2026 - Rudi's View

Latest Medical Equipment & Devices News

1
Strong ResMed Result Comes With Caveats

Nov 03 2026 - Australia
2
Vitrafy Eyes US Blood Breakthrough

Oct 06 2026 - Small Caps
3
Undervalued Catapult Sports Plays A Bigger Game

Sep 16 2026 - Small Caps
4
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
5
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
6
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
7
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
8
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
9
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
10
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia